EP1387687A4 - Nouvelle utilisation - Google Patents

Nouvelle utilisation

Info

Publication number
EP1387687A4
EP1387687A4 EP02731870A EP02731870A EP1387687A4 EP 1387687 A4 EP1387687 A4 EP 1387687A4 EP 02731870 A EP02731870 A EP 02731870A EP 02731870 A EP02731870 A EP 02731870A EP 1387687 A4 EP1387687 A4 EP 1387687A4
Authority
EP
European Patent Office
Prior art keywords
novel use
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02731870A
Other languages
German (de)
English (en)
Other versions
EP1387687A2 (fr
Inventor
Douglas William Pierre Hay
Gareth J Sanger
Tadataka Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0112208A external-priority patent/GB0112208D0/en
Priority claimed from GB0129268A external-priority patent/GB0129268D0/en
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1387687A2 publication Critical patent/EP1387687A2/fr
Publication of EP1387687A4 publication Critical patent/EP1387687A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP02731870A 2001-05-18 2002-05-17 Nouvelle utilisation Withdrawn EP1387687A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0112208A GB0112208D0 (en) 2001-05-18 2001-05-18 New use
GB0112208 2001-05-18
GB0129268 2001-12-06
GB0129268A GB0129268D0 (en) 2001-12-06 2001-12-06 Novel use
PCT/US2002/015911 WO2002094187A2 (fr) 2001-05-18 2002-05-17 Nouvelle utilisation

Publications (2)

Publication Number Publication Date
EP1387687A2 EP1387687A2 (fr) 2004-02-11
EP1387687A4 true EP1387687A4 (fr) 2006-07-05

Family

ID=26246093

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02731870A Withdrawn EP1387687A4 (fr) 2001-05-18 2002-05-17 Nouvelle utilisation

Country Status (19)

Country Link
EP (1) EP1387687A4 (fr)
JP (1) JP2004534761A (fr)
KR (1) KR20040016865A (fr)
CN (1) CN1269483C (fr)
AR (1) AR045879A1 (fr)
AU (1) AU2002303811B2 (fr)
BR (1) BR0209662A (fr)
CA (1) CA2447063A1 (fr)
CZ (1) CZ20033115A3 (fr)
HU (1) HUP0400966A2 (fr)
IL (1) IL158701A0 (fr)
MX (1) MXPA03010509A (fr)
MY (1) MY134211A (fr)
NO (1) NO20035121L (fr)
NZ (1) NZ529462A (fr)
PE (1) PE20021067A1 (fr)
PL (1) PL367308A1 (fr)
TW (1) TWI243678B (fr)
WO (1) WO2002094187A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1911763B1 (fr) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions pour le traitement de troubles gastrointestinaux
AU2005231355B2 (en) * 2004-03-30 2008-09-18 Smithkline Beecham Corporation Spray dried pharmaceutical compositions
WO2005100997A2 (fr) * 2004-04-16 2005-10-27 Bayer Healthcare Ag Moyens diagnostiques et therapeutiques pour maladies associees au recepteur de tachykinine 3 (tacr3)
JP2009510121A (ja) * 2005-09-30 2009-03-12 スミスクライン・ビーチャム・コーポレイション 医薬組成物
TW200804288A (en) 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
WO2018129556A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
KR200452372Y1 (ko) * 2010-05-14 2011-02-22 서일수 건설용 리프트의 통신선 지지장치
KR101034774B1 (ko) * 2010-07-30 2011-05-17 (주)챔피온코리아 와이어로프를 이용한 리프트 장치
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
WO2014170648A1 (fr) 2013-04-19 2014-10-23 Astrazeneca Ab Composé antagoniste du récepteur nk3 (nk3ra) utilisé dans une méthode pour traiter le syndrome des ovaires polykystiques (sopk)
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0673928A1 (fr) * 1994-03-18 1995-09-27 Sanofi Nouveaux dérivés de la N-(3,4-dichlorophényl-propyl)-pipéridine comme antagonistes sélectifs du récepteur NK3 humain
WO1995028931A1 (fr) * 1994-04-26 1995-11-02 Merck & Co., Inc. Azacycles spiro-substitues utilises en tant qu'antagonistes de neurokinine-3
WO1997019926A1 (fr) * 1995-11-24 1997-06-05 Smithkline Beecham S.P.A. Nouveaux derives de quinoline-4-carboxamide, leur preparation et leur utilisation en tant qu'antagonistes des recepteurs des neurokinines 3 (nk-3) et des neurokinines 2 (nk-2)
WO1998052942A1 (fr) * 1997-05-23 1998-11-26 Smithkline Beecham S.P.A. Nouveaux composes
WO2000031037A1 (fr) * 1998-11-20 2000-06-02 Smithkline Beecham S.P.A. Derives de quinoline-4-carboxamide utilises comme antagonistes des recepteurs nk-3 et nk-2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0673928A1 (fr) * 1994-03-18 1995-09-27 Sanofi Nouveaux dérivés de la N-(3,4-dichlorophényl-propyl)-pipéridine comme antagonistes sélectifs du récepteur NK3 humain
WO1995028931A1 (fr) * 1994-04-26 1995-11-02 Merck & Co., Inc. Azacycles spiro-substitues utilises en tant qu'antagonistes de neurokinine-3
WO1997019926A1 (fr) * 1995-11-24 1997-06-05 Smithkline Beecham S.P.A. Nouveaux derives de quinoline-4-carboxamide, leur preparation et leur utilisation en tant qu'antagonistes des recepteurs des neurokinines 3 (nk-3) et des neurokinines 2 (nk-2)
WO1998052942A1 (fr) * 1997-05-23 1998-11-26 Smithkline Beecham S.P.A. Nouveaux composes
WO2000031037A1 (fr) * 1998-11-20 2000-06-02 Smithkline Beecham S.P.A. Derives de quinoline-4-carboxamide utilises comme antagonistes des recepteurs nk-3 et nk-2

Also Published As

Publication number Publication date
KR20040016865A (ko) 2004-02-25
CZ20033115A3 (cs) 2004-09-15
WO2002094187A3 (fr) 2003-05-30
EP1387687A2 (fr) 2004-02-11
IL158701A0 (en) 2004-05-12
WO2002094187A2 (fr) 2002-11-28
PL367308A1 (en) 2005-02-21
JP2004534761A (ja) 2004-11-18
AU2002303811B2 (en) 2005-07-07
CN1509175A (zh) 2004-06-30
PE20021067A1 (es) 2003-02-02
MXPA03010509A (es) 2004-03-02
NZ529462A (en) 2005-07-29
MY134211A (en) 2007-11-30
HUP0400966A2 (hu) 2004-08-30
TWI243678B (en) 2005-11-21
BR0209662A (pt) 2004-04-20
NO20035121D0 (no) 2003-11-17
NO20035121L (no) 2003-11-17
CA2447063A1 (fr) 2002-11-28
CN1269483C (zh) 2006-08-16
AR045879A1 (es) 2005-11-16

Similar Documents

Publication Publication Date Title
HU0401339D0 (en) Novel 4-anilinoquinoline-3-carboxamides
EP1387687A4 (fr) Nouvelle utilisation
GB0125088D0 (en) New use
GB0100762D0 (en) Novel use
GB0115181D0 (en) Novel use
GB0104554D0 (en) New uses
EG23036A (en) Novel pyrrolecarboxamides
GB0106031D0 (en) Use
PL364076A1 (en) Novel pyridylmethylaminopyrimidines
PL367864A1 (en) Novel combination
GB0119920D0 (en) New use
GB0129268D0 (en) Novel use
GB0129266D0 (en) Novel use
GB0119022D0 (en) Novel use
GB0118919D0 (en) Novel use
GB0100852D0 (en) Novel use
GB0103899D0 (en) Use
GB0126186D0 (en) Use
GB0102482D0 (en) Use
GB0103892D0 (en) Use
GB0108115D0 (en) Use
GB0129834D0 (en) New use
GB0112208D0 (en) New use
GB0115598D0 (en) New use
GB0117913D0 (en) New use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031027

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20060606

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/00 20060101ALI20060531BHEP

Ipc: A61K 31/47 20060101AFI20060531BHEP

17Q First examination report despatched

Effective date: 20080520

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080926